Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 7/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 7/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.38 |
| ▸ | NQO2 | P16083 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29589926 | 1.00 | NPC1 (0.48) | NPC1RAB9ABCHEACHEKEAP1 | |
| SCHEMBL5215644 | 0.86 | NPC1 (0.66) | NPC1RAB9ABCHEACHEKEAP1 | |
| SCHEMBL27091299 | 0.82 | NPC1 (0.43) | NPC1RAB9A | |
| SCHEMBL29589510 | 0.82 | NPC1 (0.43) | NPC1RAB9A | |
| SCHEMBL30616938 | 0.77 | HSP90AA1 (0.49) | NPC1RAB9AKEAP1NFE2L2HSP90AA1 | |
| SCHEMBL29077753 | 0.77 | HSP90AA1 (0.49) | NPC1RAB9AKEAP1NFE2L2HSP90AA1 | |
| SCHEMBL29833108 | 0.73 | KEAP1 (0.53) | NPC1RAB9AKEAP1NFE2L2HSP90AA1 | |
| SCHEMBL5217700 | 0.71 | NPC1 (0.45) | NPC1RAB9ABCHESMN1; SMN2ABCG2 | |
| SCHEMBL5217224 | 0.69 | MKNK1 (0.52) | NPC1RAB9ABCHEMAPTSMN1; SMN2 | |
| SCHEMBL30935045 | 0.66 | MEN1 (0.53) | NPC1RAB9AKEAP1NFE2L2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240050428-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-15 | — | — | US | disclosed |
| CN-116583509-A | Compounds and methods for treating cancer | 上海睿跃生物科技有限公司 | 2023-08-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240050428-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | GSPT1, GGT1, VHL | NPC1 716/4885RAB9A 2065/4885BCHE 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.